Effect of TGF-(beta)2 and Anti-TGF(beta)2 antibody in a new in vivo rodent model of posterior capsule opacification

Noemi Lois, Julie Ann Taylor, John Vincent Forrester, G. C. Smith, R. J. van't Hof, A. D. McKinnon

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

PURPOSE. This study evaluated the effect of transforming growth factor (TGF)-beta 2 and anti-TGF-beta 2 antibody in a rodent model of posterior capsule opacification (PCO).

METHODS. An extracapsular lens extraction (ECLE) was performed in 72 Sprague - Dawley rats. At the end of the procedure, 10 mu L TGF-beta 2 (TGF-beta 2-treated group), fetal calf serum (FCS)/phosphate-buffered saline (PBS; FCS/PBS-treated control group), a human monoclonal TGF-beta 2 antibody ( anti - TGF-beta 2 treated group), or a null control IgG4 antibody ( null antibody treated control group) was injected into the capsule. Animals were killed 3 and 14 days postoperatively. Eyes were evaluated clinically prior to euthanatization, then enucleated and processed for light microscopy and immunohistochemistry afterward. PCO was evaluated clinically and histopathologically. Student's t-test and chi(2) were used to assess differences between groups.

RESULTS. There were no statistically significant clinical or histopathological differences in degree of PCO between the TGF-beta 2 - and FCS/PBS-treated groups at 3 and 14 days after ECLE. Nor were there differences between the anti - TGF-beta 2 - and the null antibody - treated groups, with the exception of the histopathology score for capsule wrinkling 3 days after ECLE ( P = 0.02). alpha-Smooth-muscle actin staining was observed in the lens capsular bag only in areas where there was close contact with the iris.

CONCLUSIONS. No sustained effect of TGF-beta 2 or anti - TGF-beta 2 antibody on PCO was found in rodents at the dose and timing administered in this study. Iris cells may play a role in the process of epithelial mesenchymal transition linked to PCO.

Original languageEnglish
Pages (from-to)4260-4266
Number of pages6
JournalInvestigative Ophthalmology & Visual Science
Volume46
DOIs
Publication statusPublished - 2005

Keywords

  • GROWTH-FACTOR-BETA
  • LENS EPITHELIAL-CELLS
  • SMOOTH MUSCLE ACTIN
  • HUMAN AQUEOUS-HUMOR
  • TGF-BETA
  • EXTRACELLULAR-MATRIX
  • CATARACT
  • PROLIFERATION
  • EXPRESSION
  • TRANSDIFFERENTIATION

Cite this

Effect of TGF-(beta)2 and Anti-TGF(beta)2 antibody in a new in vivo rodent model of posterior capsule opacification. / Lois, Noemi; Taylor, Julie Ann; Forrester, John Vincent; Smith, G. C.; van't Hof, R. J.; McKinnon, A. D.

In: Investigative Ophthalmology & Visual Science, Vol. 46, 2005, p. 4260-4266.

Research output: Contribution to journalArticle

Lois, Noemi ; Taylor, Julie Ann ; Forrester, John Vincent ; Smith, G. C. ; van't Hof, R. J. ; McKinnon, A. D. / Effect of TGF-(beta)2 and Anti-TGF(beta)2 antibody in a new in vivo rodent model of posterior capsule opacification. In: Investigative Ophthalmology & Visual Science. 2005 ; Vol. 46. pp. 4260-4266.
@article{59878f31862f48f1b1c1563b975f8cd5,
title = "Effect of TGF-(beta)2 and Anti-TGF(beta)2 antibody in a new in vivo rodent model of posterior capsule opacification",
abstract = "PURPOSE. This study evaluated the effect of transforming growth factor (TGF)-beta 2 and anti-TGF-beta 2 antibody in a rodent model of posterior capsule opacification (PCO).METHODS. An extracapsular lens extraction (ECLE) was performed in 72 Sprague - Dawley rats. At the end of the procedure, 10 mu L TGF-beta 2 (TGF-beta 2-treated group), fetal calf serum (FCS)/phosphate-buffered saline (PBS; FCS/PBS-treated control group), a human monoclonal TGF-beta 2 antibody ( anti - TGF-beta 2 treated group), or a null control IgG4 antibody ( null antibody treated control group) was injected into the capsule. Animals were killed 3 and 14 days postoperatively. Eyes were evaluated clinically prior to euthanatization, then enucleated and processed for light microscopy and immunohistochemistry afterward. PCO was evaluated clinically and histopathologically. Student's t-test and chi(2) were used to assess differences between groups.RESULTS. There were no statistically significant clinical or histopathological differences in degree of PCO between the TGF-beta 2 - and FCS/PBS-treated groups at 3 and 14 days after ECLE. Nor were there differences between the anti - TGF-beta 2 - and the null antibody - treated groups, with the exception of the histopathology score for capsule wrinkling 3 days after ECLE ( P = 0.02). alpha-Smooth-muscle actin staining was observed in the lens capsular bag only in areas where there was close contact with the iris.CONCLUSIONS. No sustained effect of TGF-beta 2 or anti - TGF-beta 2 antibody on PCO was found in rodents at the dose and timing administered in this study. Iris cells may play a role in the process of epithelial mesenchymal transition linked to PCO.",
keywords = "GROWTH-FACTOR-BETA, LENS EPITHELIAL-CELLS, SMOOTH MUSCLE ACTIN, HUMAN AQUEOUS-HUMOR, TGF-BETA, EXTRACELLULAR-MATRIX, CATARACT, PROLIFERATION, EXPRESSION, TRANSDIFFERENTIATION",
author = "Noemi Lois and Taylor, {Julie Ann} and Forrester, {John Vincent} and Smith, {G. C.} and {van't Hof}, {R. J.} and McKinnon, {A. D.}",
year = "2005",
doi = "10.1167/iovs.05-0168",
language = "English",
volume = "46",
pages = "4260--4266",
journal = "Investigative Ophthalmology & Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",

}

TY - JOUR

T1 - Effect of TGF-(beta)2 and Anti-TGF(beta)2 antibody in a new in vivo rodent model of posterior capsule opacification

AU - Lois, Noemi

AU - Taylor, Julie Ann

AU - Forrester, John Vincent

AU - Smith, G. C.

AU - van't Hof, R. J.

AU - McKinnon, A. D.

PY - 2005

Y1 - 2005

N2 - PURPOSE. This study evaluated the effect of transforming growth factor (TGF)-beta 2 and anti-TGF-beta 2 antibody in a rodent model of posterior capsule opacification (PCO).METHODS. An extracapsular lens extraction (ECLE) was performed in 72 Sprague - Dawley rats. At the end of the procedure, 10 mu L TGF-beta 2 (TGF-beta 2-treated group), fetal calf serum (FCS)/phosphate-buffered saline (PBS; FCS/PBS-treated control group), a human monoclonal TGF-beta 2 antibody ( anti - TGF-beta 2 treated group), or a null control IgG4 antibody ( null antibody treated control group) was injected into the capsule. Animals were killed 3 and 14 days postoperatively. Eyes were evaluated clinically prior to euthanatization, then enucleated and processed for light microscopy and immunohistochemistry afterward. PCO was evaluated clinically and histopathologically. Student's t-test and chi(2) were used to assess differences between groups.RESULTS. There were no statistically significant clinical or histopathological differences in degree of PCO between the TGF-beta 2 - and FCS/PBS-treated groups at 3 and 14 days after ECLE. Nor were there differences between the anti - TGF-beta 2 - and the null antibody - treated groups, with the exception of the histopathology score for capsule wrinkling 3 days after ECLE ( P = 0.02). alpha-Smooth-muscle actin staining was observed in the lens capsular bag only in areas where there was close contact with the iris.CONCLUSIONS. No sustained effect of TGF-beta 2 or anti - TGF-beta 2 antibody on PCO was found in rodents at the dose and timing administered in this study. Iris cells may play a role in the process of epithelial mesenchymal transition linked to PCO.

AB - PURPOSE. This study evaluated the effect of transforming growth factor (TGF)-beta 2 and anti-TGF-beta 2 antibody in a rodent model of posterior capsule opacification (PCO).METHODS. An extracapsular lens extraction (ECLE) was performed in 72 Sprague - Dawley rats. At the end of the procedure, 10 mu L TGF-beta 2 (TGF-beta 2-treated group), fetal calf serum (FCS)/phosphate-buffered saline (PBS; FCS/PBS-treated control group), a human monoclonal TGF-beta 2 antibody ( anti - TGF-beta 2 treated group), or a null control IgG4 antibody ( null antibody treated control group) was injected into the capsule. Animals were killed 3 and 14 days postoperatively. Eyes were evaluated clinically prior to euthanatization, then enucleated and processed for light microscopy and immunohistochemistry afterward. PCO was evaluated clinically and histopathologically. Student's t-test and chi(2) were used to assess differences between groups.RESULTS. There were no statistically significant clinical or histopathological differences in degree of PCO between the TGF-beta 2 - and FCS/PBS-treated groups at 3 and 14 days after ECLE. Nor were there differences between the anti - TGF-beta 2 - and the null antibody - treated groups, with the exception of the histopathology score for capsule wrinkling 3 days after ECLE ( P = 0.02). alpha-Smooth-muscle actin staining was observed in the lens capsular bag only in areas where there was close contact with the iris.CONCLUSIONS. No sustained effect of TGF-beta 2 or anti - TGF-beta 2 antibody on PCO was found in rodents at the dose and timing administered in this study. Iris cells may play a role in the process of epithelial mesenchymal transition linked to PCO.

KW - GROWTH-FACTOR-BETA

KW - LENS EPITHELIAL-CELLS

KW - SMOOTH MUSCLE ACTIN

KW - HUMAN AQUEOUS-HUMOR

KW - TGF-BETA

KW - EXTRACELLULAR-MATRIX

KW - CATARACT

KW - PROLIFERATION

KW - EXPRESSION

KW - TRANSDIFFERENTIATION

U2 - 10.1167/iovs.05-0168

DO - 10.1167/iovs.05-0168

M3 - Article

VL - 46

SP - 4260

EP - 4266

JO - Investigative Ophthalmology & Visual Science

JF - Investigative Ophthalmology & Visual Science

SN - 0146-0404

ER -